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Effects of Treatment on IgE Responses against Parasite Allergen-Like
Proteins and Immunity to Reinfection in Childhood Schistosome and
Hookworm Coinfections
Angela Pinot de Moira,a Frances M. Jones,a Shona Wilson,a Edridah Tukahebwa,b Colin M. Fitzsimmons,a Joseph K. Mwatha,c
Jeffrey M. Bethony,d Narcis B. Kabatereine,b David W. Dunnea
Department of Pathology, University of Cambridge, Cambridge, United Kingdoma; Vector Control Division, Ministry of Health, Kampala, Ugandab; Centre for
Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi, Kenyac; Department of Microbiology, Immunology, and Tropical Medicine, George
Washington University, Washington, DC, USAd
Naturally occurring human immunity to both schistosomiasis and hookworm infection has been associated with IgE re-
sponses against parasite allergen-like proteins. Since the two helminths frequently coinfect the same individuals, there is
growing advocacy for their concurrent treatment. However, both helminths are known to exert strong immunomodulatory
effects; therefore, coinfected individuals could have immune responses different from those characteristically seen in
monoinfected individuals. In this study, we measured changes in IgE, IgG1, and IgG4 responses to schistosome and hook-
worm antigens, including the allergen-like proteins Schistosoma mansoni tegumental-allergen-like 1 protein (SmTAL1),
SmTAL2, and Necator americanus Ancylostoma-secreted protein-2 (Na-ASP-2), following concurrent treatment of school-
children coinfected with Schistosoma mansoni and hookworm. Antibody responses to schistosome egg (soluble egg anti-
gen and SmTAL2) or somatic adult hookworm (AHW) antigens either decreased after treatment or were unchanged,
whereas those to schistosome worm antigens (soluble worm antigen and SmTAL1) increased. The observed different ef-
fects of treatment likely reflect the different modes of drug action and sites of infection for these two helminths. Impor-
tantly, there was no evidence that the simultaneous treatment of coinfected children with praziquantel and albendazole
affected schistosome- and hookworm-specific humoral responses differently from those characteristic of populations in
which only one organism is endemic; schistosome- and hookworm-specific responses were not associated, and there was
no evidence for cross-regulation. Posttreatment increases in the levels of IgE to schistosome worm antigens were associ-
ated with lower Schistosoma mansoni reinfection intensity, while no associations between humoral responses to AHW an-
tigen and protection from hookworm reinfection were observed in this sample of school-aged children.
Schistosomiasis and hookworms are estimated to affect about207million and 740million people worldwide, respectively (1,
2). Although there is effective chemotherapy for both infections,
treatment is insufficient to halt transmission and individuals re-
main susceptible to reinfection after treatment. However, age-
infection profiles observed among populations in which the dis-
eases are endemic provide epidemiological evidence that a natural
age-dependent partial immunity can develop to both helminth
infections (3, 4).
For both helminth infections, this immunity has been associ-
ated with specific IgE responses to crude and defined parasite
antigens. In schistosomiasis, IgE to adult worm antigens has been
associated with resistance to reinfection (5–8); these responses
tend to increase with age and after chemotherapeutic treatment in
populations in which the disease is endemic (9, 10). In hookworm
infection, negative relationships between both total and specific
IgE and worm weight, fecundity, and heavy hookworm infection
have been described (11, 12). In contrast to schistosomiasis, there
is little evidence for treatment boosting of antibody responses;
instead, responses tend to decrease posttreatment (13, 14).
In both helminth infections, IgE responses to a number of
defined antigens are strongly associated with immunity (5, 15,
16), andmany of these antigens share structural homology with
allergens (17). For example, IgE to Schistosoma mansoni tegu-
mental-allergen-like 1 protein (SmTAL1-IgE) is a marker for
human immunity in schistosomiasis mansoni (5, 16); SmTAL1
is a member of the TAL family, a group of proteins sharing
structural homology with the EF hand allergens, one of the
most common groups of clinical allergens (9). In necatoriasis
americanus, negative associations between IgE to the recombi-
nant larval protein Necator americanus Ancylostoma-secreted
protein-2 (Na-ASP-2) and heavy infection intensity have been
described (11); Na-ASP-2 shares structural homology with the
pathogenesis-related 1 (PR-1) allergens, the majority of which
are derived from insect venoms (18).
While in allergy similar IgE responses are associated with se-
vere pathology, in helminth infection, strong immunomodula-
tory effects, including regulatory cells and cytokines, and also
IgG4, which is capable of blocking IgE-allergen complex forma-
tion (19; reviewed in references20, 21, and22), limit IgE-mediated
morbidity. Although this immunoregulation reduces pathology
during chronic infection and may also offer protection against
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allergy and autoimmune disease (reviewed in references20, 22,
and23), it can also influence immune responses to vaccines (24,
25), coinfecting microparasites (26), and also coinfecting hel-
minths (27, 28). Despite helminth-helminth coinfection often be-
ing the norm in tropical regions (29–31) and the potential impli-
cations that this may have for vaccine development and control
programs, relatively few studies have investigated the immunol-
ogy of helminth coinfections. Animal studies generally suggest
that infection with a Schistosoma sp. may have protective effects
against other helminth coinfections (32–34), while human studies
point toward downmodulation of specific immune responses
among coinfected individuals (27, 28). For example, Geiger et al.
observed further downmodulation of hookworm-specific Th1 cy-
tokine responses among individuals coinfected with S. mansoni or
Ascaris lumbricoides, and although coinfected individuals also had
higher levels of both hookworm-specific IgE and IgG4, correla-
tions between hookworm infection intensity and hookworm-spe-
cific IgG4 were also stronger among these individuals (28). A
number of studies have also indicated an increased risk of concur-
rent schistosome-hookworm infection in populations in which
both organisms are endemic (35–37) and a propensity toward
heavier infection among coinfected individuals (38).
In the current study, we examined posttreatment parasite-spe-
cific immunological changes and whether helminth coinfection
influences these changes and subsequent reinfection immunity.
The study was conducted among school-aged children living in
the same community where both diseases are endemic and receiv-
ing treatment for schistosomiasis and hookworm as part of the
Ugandan national control program. In these children, we com-
pared the effects of concurrent praziquantel and albendazole
treatment on IgE, IgG1, and IgG4 responses to defined schisto-
somal andhookwormantigens derived fromdifferent stages of the
life cycle, including the allergen-like proteins SmTAL1, SmTAL2,
and Na-ASP-2. Findings will help establish the nature of the im-
mune response to these infections after treatment in a setting in
which both diseases are endemic andwhether there is evidence for
cross-regulation and influences on reinfection immunity.
MATERIALS AND METHODS
Study area and population. This study was conducted among children
aged 7 to 16 years attending Bwondha Primary School in Bwondha Vil-
lage, located along the shoreline of Lake Victoria inMayuge District, east-
ern Uganda. As part of the Ugandan national control program, praziqu-
antel and albendazole are administered to all schoolchildren by teachers
annually and biannually, respectively (39).
The principal water sources in Bwondha are the lake and shallowwells;
boreholes are used by a small minority. Sanitation is poor: 33% of
households have access to a pit latrine.
Parasitological surveys. A register of all children (n 795) attending
Bwondha Primary School was drawn up; from this, a simple random
sample of 350 children aged 7 to 16 years was selected. A socioeconomic
questionnaire was translated to Luganda (the principle language) and
administered to the most relevant parent/guardian.
From the endof July 2010, childrenwere treatedwith albendazole (400
mg) and twice with praziquantel (40mg/kg of body weight), 1 week apart;
in line with national guidelines, children were treated again for hook-
worm 6 months after the initial treatment. Venous blood samples (5 ml)
were collected from children before the initial treatment and 8 weeks after
treatment, and stool sampleswere collected for parasitology prior to treat-
ment and 5 weeks, 6 months, and 12 months after the second dose of
initial treatment. Stool samples collected at 5 weeks were used to detect
treatment failure or noncompliance and determine treatment efficacy. All
stool samples were collected on three consecutive days, and two 50-mg
Kato-Katz (40) slides were prepared from each day’s sample and exam-
ined microscopically (within 30 min for hookworm quantification).
Parasite antigens. A Puerto Rican strain of S. mansoni, maintained in
outbred mice and Biomphalaria glabrata, was used for production of na-
tive schistosome antigens. Adult worms were recovered from mice by
portal perfusion 6 weeks after infection, and parasite eggs were isolated
from liver tissue. Soluble worm antigen (SWA) was prepared from frozen
parasites, and saline-soluble egg antigen (SEA) was prepared from frozen
eggs, all as previously described (23, 41). The recombinant schistosome
antigens SmTAL1 (Sm22.6) and SmTAL2 (Sm21.7) were prepared as pre-
viously described (5, 16). Somatic adult hookworm (AHW) crude antigen
extract was derived from Ancylostoma caninum, taken from canines. Na-
ASP-2, an excretory-secretory (ES) product released by third-stageNeca-
tor americanus larvae, was expressed in Pichia pastoris as previously de-
scribed (11, 42).
Antibody assays. Plasma was removed from venous blood samples
and stored at80°C until required. Levels of IgE, IgG1, and IgG4 to SEA,
SWA, SmTAL1, SmTAL2, AHW, andNa-ASP-2 antigens were measured
by enzyme-linked immunosorbent assay (ELISA) as described elsewhere
(9). Briefly, 384-well plates were coated with 15 l/well of antigen at
saturation coating concentrations of 1.2 g/ml (SEA), 8 g/ml (SWA),
2.75 g/ml (SmTAL1), 3.8 g/ml (SmTAL2), 5 g/ml (AHW), and 5
g/ml (Na-ASP-2), as determined by titration. Fifteenmicroliters of sam-
ple plasma andplasma fromnoninfected controlswas assayed in duplicate
at dilutions of 1/20 for IgE and 1/200 for IgG1 and IgG4. A 3-fold serial
dilution of purified human IgG1 or IgG4 (Sigma-Aldrich) or IgE my-
eloma (Calbiochem) was added directly to each plate to form a 14-point
standard curve, starting at 30 g/ml.
For schistosome antigen assays, detection was as described previously
(9). For AHW andNa-ASP-2 assays, horseradish peroxidase (HRP)-con-
jugated mouse anti-human IgG1, mouse anti-human IgG4-HRP (Invit-
rogen), or polyclonal goat anti-human IgE-HRP (ABD Serotec) was used
for detection. Plates were read at dual wavelengths of 490 and 630 nm on
a Powerwave HT microplate reader (BioTek Instruments Inc.). Results
were interpolated from the standard curves with a 5-parameter curve fit
using Gen5 analysis software (BioTek Instruments Inc.).
Statistical analysis. Infection intensity was expressed as the mean egg
count per gram (epg). Due to overdispersion, epg values were trans-
formed to the logarithm, ln(epg 1), and geometric means (GMs) were
calculated. Details relating to household economic characteristics (house
construction, sources of water, sanitation, and asset ownership)were used
to construct a proxy measure of economic status, using principle compo-
nent analysis, as described previously (43, 44). Scores were ranked and
divided into tertiles, allowing households to be classified as low,middle, or
high economic status.
Detection thresholds for ELISA readings for each antigen and isotype
assayed were calculated as the mean plus 3 standard deviations of nonin-
fected European control plasma samples. Readings were analyzed as the
logarithm, with the detection threshold added to remove nonpositive
numbers. Changes to isotype responses after treatment were calculated as
the difference in log pre- and posttreatment antibody levels. These were
analyzed in three ways: (i) significance in changes was tested using paired
t tests, (ii) differences in changes by age group (10 years versus 10
years) were determined using two-sample t tests, and (iii) associations
between antibody changes and pretreatment infection intensity [ln(epg
1)] and how this varied by age group were determined using multiple-
regression analysis, adjusting for age and sex, with an interaction term
between ln(epg 1) and age.
Multiple regressions were used to investigate associations between an-
tibody changes and reinfection [ln(epg 1)] among children infected at
baseline, adjusting for age, sex, and treatment efficacy [5-week ln(epg 
1)] as a priori confounders; other variables were assessed by forward se-
lection; no other significant risk factors were found. For hookworm, since
the rate of reinfection at 6 months was relatively low (50%), zero-in-
Pinot de Moira et al.
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flated negative-binomial models were used. For all analyses, age was clas-
sified into two binary groups of roughly equal size: 7 to 10 years and 11 to
16 years.
All analyses were conducted using the Stata (version 10.1) program
(StataCorp).
Ethical clearance and informed consent. Ethical clearance was ob-
tained from the Uganda National Council of Science and Technology.
Written informed consent was obtained from all parents/guardians of the
selected children.
RESULTS
Consent was obtained from the parents or guardian of 277 (79%)
of the 350 selected children; 4 of them either failed to comply with
or respond to treatment. Of the remaining 273 children, 240
(96%) donated blood at baseline and 8 weeks posttreatment; 179
(75% of 240) and 155 (65%) were present, respectively, for the 6-
and 12-month parasitology surveys. Therewas some evidence that
consenting children were slightly older than nonconsenting chil-
dren (10.4 versus 9.8 years of age); otherwise, children lost to
follow-up were not significantly different (results not shown).
The overall pretreatment rates of prevalence of S. mansoni and
hookworm infection were high: 93.8% (95% confidence interval
[CI], 89.9 to 96.5) and 80.4% (95% CI, 74.8 to 85.2), respectively.
The prevalence of S. mansoni and hookworm coinfection was
74.6% (95% CI, 68.6 to 80.0). Both S. mansoni and hookworm
infection intensities were lower among monoinfected children
(Table 1), but not to the extent of significance [age-, sex-, and
socioeconomic status-adjusted S. mansoni GM (epg 1) ratio
0.80 (95%CI, 0.44 to 1.46; P 0.46) and adjusted hookwormGM
ratio 0.85 (95%CI, 0.29 to 2.51) for monoinfected versus coin-
fected groups].
The overall cure rate for S. mansoni infection in Bwondha
was relatively low (45.5%), but among those with detectable
infection at 5 weeks posttreatment, infection intensity was
markedly reduced (GM epg  16.43 [95% CI, 12.66, 21.33]
compared with GM epg  363.49 [95% CI, 271.22, 487.14]
before treatment). S. mansoni cure rates increased significantly
with age (likelihood ratio [LR] test for trend, P  0.01), from
29.6% at 7 to 8 years to 58.3% at 13 to 16 years. The overall cure
rate for hookworm infection was 79.4%, with no significant age
association (P  0.64).
The posttreatment S. mansoni infection prevalence and inten-
sity were significantly lower among older children (P 0.01; Ta-
ble 1); both before and after treatment, infection intensities fol-
lowed a convex relationship with age, peaking at about age 10
years (Fig. 1A). The prevalence and intensity of hookworm infec-
tion showed no clear association with age (P 0.10; Table 1 and
Fig. 1B). Hookworm infection also showed no association with
socioeconomic background, whereas the S. mansoni infection
prevalence and intensity decreasedwith increasing socioeconomic
status in a quadratic relationship (Table 1).
Parasite-specific antibody profiles over age. Pretreatment
mean levels of the antibody isotype to each of the antigens mea-
sured are displayed by age in Fig. 2. There was some evidence that
mean anti-SWA IgE and anti-AHW IgG4 responses increased
with age and that mean anti-SEA IgG1 responses declined with
age, but generally, no significant trends were observed. Of note
was the lack of a detectable anti-Na-ASP-2 IgE response among
children.
Also displayed in Fig. 2 are the 8-week posttreatment mean
antigen-specific isotype levels, with the changes following treat-
ment quantified in Table 2. Treatment had the effect of signifi-
cantly increasing mean levels of IgE, IgG1, and IgG4 to SWA;
responses to TAL1, a protein mainly expressed in the adult worm,
increased predominately in older children (age, 10 years; P 
0.001). In contrast, responses toAHWcrude antigen extract either
were not significantly affected by treatment (anti-AHW IgE) or
were markedly reduced posttreatment (anti-AHW IgG1 and anti-
AHW IgG4; P 0.001). Similarly, levels of IgE to S. mansoni egg
antigens were not significantly affected by treatment, while anti-
SEA IgG1 and IgG4 levels significantly decreased following treat-
ment (Table 2).
Mean levels of IgG4 to SmTAL2, a protein expressed through-
out the S. mansoni life cycle, rose after treatment (P 0.04), while
anti-SmTAL2 IgE and IgG1 levels were not significantly affected
by treatment. Responses to Na-ASP-2 were also unaffected by
treatment: anti-Na-ASP-2 IgG1 and anti Na-ASP-2 IgG4 levels
were not significantly different posttreatment, and as was the case
before treatment, none of the children mounted an anti-Na-
ASP-2 IgE response. To ensure that the absence of a detectable
anti-Na-ASP-2 IgE response among children was not due to an
assay failure, we repeated the assay using sera from a previous
study of children and adults (9) conducted in a similar Lake Vic-
toria village where the two infections are coendemic. Few children
had detectable anti-Na-ASP-2 IgE levels (25%), but IgE re-
sponses were clearly detected among adults (38%) (Fig. 3).
Table 3 displays the influence of pretreatment infection inten-
sity on observed posttreatment antigen-specific antibody boosts.
Posttreatment increases in anti-SWA IgG1, anti-TAL1 IgG1 and
IgG4, and anti-TAL2 IgG4 titers were associated with pretreat-
ment S. mansoni infection intensity, with greater increases ob-
served amongmore heavily infected children (P 0.01). Boosts in
anti-TAL1 IgE levels were likewise associated with heavier pre-
treatment infection intensities, but only among older children
(significant interaction, according to a 2 value [1 degree of free-
dom {df}] by the LR test of 5.08; P 0.02).
Posttreatment changes in the levels of IgG1 and IgG4 against
AHW were similarly associated with pretreatment hookworm
infection intensity but differed in that greater decreases were
observed among children with heavier pretreatment hook-
worm infections (P 0.01). For anti-AHW IgG1, this relation-
ship was much stronger among younger children (significant
interaction, according to a 2 value [1 df] by the LR test of 4.55,
P  0.03).
No associations were observed between pretreatment hook-
worm infection and posttreatment changes in schistosome-spe-
cific antibody levels, or vice versa, for pretreatment S. mansoni
infection and posttreatment changes in anti-AHW IgG1 and IgG4
levels (Table 3).
Associations between posttreatment changes in antibody
levels and reinfection. Further analysis used multiple-regres-
sion analysis to explore associations between antibody boosts
and reinfection among children infected at baseline, control-
ling for age, sex, and treatment efficacy. Stronger anti-SWA IgE
boosts were associated with significantly lower S. mansoni in-
fection intensity at 12 months posttreatment (GM ratio, 0.54
[95%CI, 0.29, 0.99]; P 0.04; Table 4). Stronger anti-SmTAL1
IgE boosts were borderline significantly associated with lower
rates of reinfection, but only after controlling for posttreat-
ment levels of anti-SmTAL1 IgG4 (GM ratio, 0.73 [95% CI,
0.53 to 1.00]; P  0.05). No other isotype changes (including
IgE Responses and Immunity in Helminth Coinfections
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for hookworm antigens) were associated with S. mansoni rein-
fection (P  0.5; results not shown).
Due to the low levels of hookworm reinfection observed, zero-
inflated negative-binomial models were used to investigate asso-
ciations between hookworm reinfection at 6 months and post-
treatment changes in antibody levels. Reinfection intensities were
significantly greater among children with sustained (i.e., less re-
duced) anti-AHW IgG1 levels (adjusted 0.21 [95%CI, 0.09 to
0.32]; P 0.001). Conversely, the risk of reinfection was reduced
among children with a sustained anti-Na-ASP-2 IgG1 response
(adjusted   0.68 [95% CI, 0.07 to 1.30]; P 0.03). Otherwise,
no associations (including with schistosome-specific antibody
boosts) were observed (P 0.1; results not shown).
DISCUSSION
Helminth infections are known to exert strong immunomodula-
tory effects on their mammalian hosts (19; reviewed in refer-
ences20, 21, and22); therefore, individuals living in regions where
both infections occur may have altered immune responses to
those characteristically seen in populations of monoendemicity.
The current study investigated changes in parasite-specific IgG1,
IgG4, and IgE responses to crude parasite extracts and defined
TABLE 1 Distribution of S. mansoni infection and hookworm infection by age and sex among children bled both before and 8 weeks after treatment
Infection and characteristic
Pretreatment 12 mo posttreatment
No.a % prevalence (95% CI)
GMb (epg 1)




Overall 240 93.8 (89.9, 96.5) 172.73 (131.61, 226.72) 155 92.9 (87.7, 96.4) 103.04 (76.54, 138.71)
Sex
Male 117 94.9 (89.2, 98.1) 217.94 (146.89, 323.35) 79 94.9 (87.5, 98.6) 133.38 (88.55, 200.90)
Female 123 92.7 (86.6, 96.6) 138.47 (95.04, 201.74) 76 90.8 (81.9, 96.2) 78.79 (51.11, 121.46)
P value 0.48 0.10 0.31 0.08
Age (yr)
7–10 118 95.8 (90.4, 98.6) 213.69 (149.66, 305.12) 73 98.6 (92.6, 100.0) 157.70 (113.01, 220.05)
11–16 122 91.8 (85.4, 96.0) 140.60 (93.22, 212.07) 82 87.8 (78.7, 94.0) 70.54 (44.14, 112.73)
P value 0.20 0.13 0.01 0.01
Socioeconomic backgroundd
Low 64 96.9 (89.2, 99.6) 245.49 (157.79, 381.94) 41 100.0 (91.4, 1e) 125.02 (79.46, 196.70)
Medium 65 96.9 (89.3, 99.6) 249.37 (154.76, 401.80) 39 92.3 (79.1, 98.4) 119.99 (66.50, 216.53)
High 61 86.9 (75.8, 94.2) 86.30 (46.49, 160.22) 39 89.7 (75.8, 97.1) 77.68 (38.51, 156.68)
P value 0.04 0.01 0.01 0.43f
Coinfection
Monoinfected 46 195.17 (117.67, 323.70) 30 93.3 (77.9, 99.2) 98.97 (48.95, 200.13)
Coinfected 179 257.78 (199.61, 332.89) 115 94.8 (89.0, 98.1) 125.21 (90.60, 173.05)
P value 0.33 0.76 0.52
Hookworm
Overall 80.4 (74.8, 85.2) 71.75 (51.52, 99.90) 179 44.7 (37.3, 52.3) 8.00 (5.43, 11.76)
Sex
Male 87.2 (79.7, 92.6) 114.67 (72.76, 180.72) 85 49.4 (38.4, 60.5) 9.94 (5.55, 17.80)
Female 74.0 (65.3, 81.5) 45.93 (28.64, 73.65) 94 40.4 (30.4, 51.0) 6.57 (3.91, 11.04)
P value 0.01 0.01 0.23 0.29
Age (yr)
7–10 84.7 (77.0, 90.7) 92.22 (59.22, 143.61) 88 43.2 (32.7, 54.2) 7.84 (4.42, 13.90)
11–16 76.2 (67.7, 83.5) 56.28 (34.38, 92.12) 91 46.2 (35.6, 56.9) 8.15 (4.79, 13.86)
P value 0.10 0.14 0.69 0.92
Socioeconomic backgroundd
Low 78.1 (66.0, 87.5) 59.47 (31.24, 113.23) 47 40.4 (26.4, 55.7) 6.67 (3.06, 14.52)
Medium 86.2 (75.3, 93.5) 111.84 (59.31, 210.89) 50 48.0 (33.7, 62.6) 10.47 (4.91, 22.34)
High 73.8 (60.9, 84.2) 48.50 (24.11, 97.57) 41 48.8 (32.9, 64.9) 7.56 (3.33, 17.13)
P value 0.21 0.17 0.67 0.68
Coinfection
Monoinfected 158.86 (54.79, 460.62) 10 50.0 (18.7, 81.3) 16.13 (1.59, 163.45)
Coinfected 207.05 (161.39, 265.61) 129 50.4 (41.5, 59.3) 10.60 (6.66, 16.85)
P value 0.57 0.98 0.63
a Among children who donated at least one stool sample at baseline.
b GM, geometric mean.
c Among children who donated at least one stool sample at 12 months posttreatment for S. mansoni and among children who donated at least one stool sample at 6 months
posttreatment for hookworm.
d Based on household characteristics (number of people sharing a sleeping room, materials used for construction, overall condition, main source of fuel for lighting and cooking,
toilet facilities, and sources of water) and asset ownership (radio, mobile phone, lantern, boat, sheep or goat, cattle, and poultry).
e One-sided, 97.5% confidence interval.
f The quadratic term was significant (P 0.02).
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allergen-like antigens following praziquantel and albendazole
treatment of schoolchildren coinfected with schistosomes and
hookworm and receiving treatment as part of a national control
program. Specifically, we measured antibody responses to schis-
tosome egg (SEA and SmTAL2) and worm (SWA and SmTAL1)
antigens, hookworm somatic adult worm crude antigen extract,
and the recombinant hookworm larval protein Na-ASP-2. Re-
sponses to schistosome antigens predominantly expressed in the
adult worm tended to increase after treatment, while those to egg
antigens generally either decreased or were unchanged by treat-
ment. In contrast to responses to schistosomal adult worm anti-
gens, antibody responses to hookworm adult somatic crude anti-
gen extract remained either unchanged or decreased following
treatment, while those to Na-ASP-2 were seemingly unaffected.
There was evidence for an association between posttreatment in-
creases in IgE responses to schistosomal worm antigens and re-
duced susceptibility to S. mansoni reinfection 12 months after
treatment. There were no observable interactions between the two
infections.
Posttreatment increases in antibody responses to adult worm
antigens have been observed in other communities where schisto-
somiasis is endemic (10, 45–47). Grogan et al. (46) suggested that
these posttreatment increases in antischistosomal worm re-
sponses could be due to either the boosting of antischistosomal
worm responses by praziquantel-induced exposure of specific
worm antigens or the removal of parasite-driven suppressive
mechanisms. The contrasting increase in schistosome worm anti-
body responses and decrease in hookworm responses when coin-
fected children are simultaneously treated strongly suggest that
these increases are exposure driven rather than due to the removal
of immunosuppressive factors. This could explain the observed
associations between pretreatment infection intensity and post-
treatment antibody boosts: a greater worm burden before treat-
ment is likely to result in greater antigenic exposure after treat-
ment. The stronger boosts to the tegumental antigen SmTAL1
observed among older children (11 to 16 years) and the significant
interaction between pretreatment infection intensity and age for
anti-TAL1 IgE boosts suggest that these boosts are age related.We
have observed age-related posttreatment anti-TAL1 and anti-
SWA boosts in other S. mansoni-infected communities (10). This
age relatedness is likely linked to the extent of previous sensitiza-
tion by exposure to normally sequestered antigens following nat-
ural or treatment-induced worm death. Age or exposure depen-
dency could explain the relatively small posttreatment anti-SWA
IgE boosts observed here among schoolchildren compared with
those that we have observed in older individuals (10).
It has been suggested that posttreatment increases in schisto-
some-specific antibody responses indicate an individual’s poten-
tial to mount a protective response when required (10). Indeed,
associations between posttreatment anti- worm IgE boosts and
resistance to reinfection have been described (45), and here, post-
treatment anti-SWA IgE increases were associated with resistance
to S. mansoni reinfection at 12 months posttreatment, indepen-
dently of age. There is evidence that increased resistance to rein-
fection can be induced by repeated rounds of praziquantel treat-
ment (41, 48),most likely due to treatment-associated exposure to
specific antigens. Hence, resistance to infection may develop
sooner among populations receiving regular treatment for schis-
tosomiasis. Since we know that the Bwondha community has re-
ceived previous treatment for schistosomiasis, the immunizing
effect of previous praziquantel treatments may explain the rela-
tively early peak in infection intensity seen in our study sample (in
those ages 9 to 10 years versus a more typical peak in those ages 13
to 16 years) (49).
In contrast to the increase in responses directed at antigens
predominantly expressed in the schistosome adult worm, anti-
SEA IgG1 and IgG4 responses fell after treatment. Unlike the po-
tentially immunizing doses of schistosome adult worm antigen
associated with treatment, levels of egg-associated antigens, to
which the immune system will be continuously exposed during
chronic infection (50), are likely to fall rather than increase after
treatment, due to the removal of adult worms.
Similarly, adult hookworm-specific antibody levels were either
unaffected by treatment (IgE) or fell after treatment (IgG1 and
IgG2). Geiger et al. observed similar reductions in anti-adult
hookworm IgG1 and IgG4 responses but similarly unaffected
anti-adult hookworm IgE levels among Necator americanus-in-
fected schoolchildren 6months after curative treatment (51). The
observed reductions in anti-AHW responses, which contrast with
those to adult schistosomes, may reflect the different sites of in-
fection for these two helminths: the small intestine versus themes-
enteric veins. They could also reflect the different modes of action
of praziquantel and albendazole. Whereas praziquantel causes
disruption of the tegument and exposure to antigen intrave-
nously, albendazole causes metabolic disruption, resulting in the
paralysis and death of worms, which are then expelled intact from
the gut; hence, albendazole-associated exposure to antigen is un-
likely. The sustained anti-AHW IgE levels observed after treat-
ment may reflect different dose effects, as postulated by Pritchard
et al., who observed analogously sustained IgE responses to adult
ES antigen at 1 year posttreatment but significant decreases in
FIG 1 Geometric mean egg counts (epg  1) for S. mansoni (A) and hook-
worm (B) before and after treatment.
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FIG 2 Geometric mean isotype responses to SWA, SmTAL1, SEA, SmTAL2, AHW, and Na-ASP-2 over age before (solid line) and 8 weeks after (dashed line)
treatment. Detection thresholds were added to values before calculating GMs to remove nonpositive values. IgE levels are expressed in ng/ml, and IgG1 and IgG4
levels are expressed in g/ml.
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anti-adult ES IgM and IgG responses (14). In experimental Nip-
postrongylus brasiliensis infection in rats, low-level infection in-
duced amore sustained specific IgE response, whereas specific IgG
levels were much more strongly associated with the dose of infec-
tion (52).
Pritchard et al. also failed to observe anymarked change in IgG
levels to larval somatic antigen (14), as similarly observed here for
anti-Na-ASP-2 IgG1 and IgG4. This is not unexpected: responses
to larval antigens are likely to reflect exposure to infection as op-
posed to chronic patent infection. Higher anti-Na-ASP-2 IgE lev-
els have been positively associated and higher anti-Na-ASP-2
IgG4 levels have been negatively associated with heavy hookworm
infection in individuals from areas with high rates of transmission
in Brazil and China (11). None of the children included in our
study produced a detectable anti-Na-ASP-2 IgE response. How-
ever, in our parallel study of children and adults, similarly few
children had detectable anti-Na-ASP-2 IgE responses, whereas
significant anti-Na-ASP-2 IgE responses were detected among
adults. From experimental human infections, it is known that an-
tihookworm IgE responses tend to develop very slowly and over
repeated exposures (53, 54).Hence, our school-aged childrenmay
not have had a sufficient history of exposure to have developed an
anti-Na-ASP-2 IgE response. Provided that anti-Na-ASP-2 IgE
responses are protective for hookworm infection, this would be
consistent with age-hookworm infection profiles, which point to-
ward the slow development of partial immunity (4).
In summary, we investigated changes in parasite-specific IgG1,
IgG4, and IgE antibody responses following praziquantel and al-
bendazole treatment of school-aged children living in a commu-
nity where schistosomiasis mansoni and hookworm are coen-
demic. Antibody responses to adult hookworm or S. mansoni
egg antigens either decreased after treatment or were un-
TABLE 2 Increase in isotype responses to SWA, SmTAL1, SEA, SmTAL2, AHW, and ASP2 following treatment among all children by age group
Antigen and antibody
All children Children10 yr of age Children10 yr of age
% boosta (95% CI) P valueb % boost (95% CI) P value % boost (95% CI) P value
SWA
IgE 7 (1, 13) 0.03 6 (2, 14) 0.14 7 (2, 17) 0.12
IgG1 69 (59, 81) 0.0001 71 (56, 88) 0.0001 68 (53, 84) 0.0001
IgG4 83 (54, 118) 0.0001 101 (57, 157) 0.0001 68 (30, 116) 0.0001
TAL1
IgE 30 (11, 51) 0.001 3 (13, 23) 0.70 61 (26, 107) 0.0002
IgG1 31 (17, 46) 0.0001 12 (1, 28) 0.09 52 (28, 80) 0.0001
IgG4 58 (37, 81) 0.0001 26 (11, 42) 0.0003 96 (54, 150) 0.0001
SEA
IgE 4 (3, 12) 0.23 7 (3, 17) 0.19 2 (8, 13) 0.67
IgG1 7 (11,2) 0.004 4 (11, 3) 0.23 10 (16,3) 0.01
IgG4 18 (28,8) 0.001 8 (22, 7) 0.27 27 (39,13) 0.001
TAL2
IgE 2 (14, 20) 0.86 3 (18, 30) 0.77 0 (22, 28) 0.99
IgG1 5 (11, 2) 0.17 9 (18, 1) 0.09 0 (8, 8) 0.94
IgG4 17 (7, 28) 0.001 17 (1, 36) 0.04 17 (4, 31) 0.01
AHW
IgE 1 (30, 44) 0.97 14 (42, 27) 0.44 18 (35, 115) 0.59
IgG1 68 (79,51) 0.0001 70 (84,42) 0.001 67 (81,41) 0.0003
IgG4 17 (22,11) 0.0001 17 (24,9) 0.0001 17 (24,9) 0.0001
ASP2
IgE
IgG1 6 (15, 4) 0.24 12 (24, 1) 0.08 1 (12, 16) 0.89
IgG4 6 (22, 15) 0.56 11 (33, 19) 0.44 0 (23, 30) 0.97
a Average percent increase in antibody responses, calculated as follows: 100	 (exp{mean[ln(posttreatment level assay cutoff) ln(pretreatment level assay cutoff)]} 1).
b Paired t test comparing ln(posttreatment level assay cutoff) with ln(pretreatment level assay cutoff).
FIG 3 Box plot displaying IgE responses toNa-ASP-2 among individuals (age
range, 7 to 76 years) in a community where schistosomiasis and hookworm are
coendemic; the figure excludes outside values.
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changed, whereas those to S. mansoni adult worm antigens
increased. Posttreatment increases in anti-adult worm IgE
were associated with reduced susceptibility to S. mansoni rein-
fection, indicating that treatment-associated boosting of im-
mune responses potentially induces schistosome reinfection
immunity. In contrast, there was little evidence for treatment-
induced IgE-mediated immunity to hookworm infection in
this cohort of children; however, given the contrasting devel-
opment of antischistosome and antihookworm IgE responses,
a wider age range may be required to demonstrate hookworm
immunity. Importantly, there was no evidence for the simulta-
neous treatment of coinfected children with praziquantel and
albendazole affecting posttreatment changes in specific anti-
body responses and subsequent reinfection immunity. Our
findings have importance for control programs conducted in
countries where the two infections are coendemic, where co-
TABLE 4 Associations between posttreatment increases in titer of IgE to
SWA and that at 12 months reinfectiona
Characteristic GM ratiob (95% CI) P valuec
Sex (male) 0.63 (0.35, 1.14) 0.53
Age (yr)
7–10
11–16 0.84 (0.47, 1.49) 0.12
Posttreatment SWA IgE
boostd
0.54 (0.29, 0.99) 0.04
ln(epg 1)e at 5 wk 1.38 (1.16, 1.64) 0.001
a Restricted to children with detectable S. mansoni eggs before treatment.
b Geometric mean (GM) ratio determined using multiple regression analysis.
c By the likelihood ratio (LR) test.
d ln(posttreatment level assay cutoff) ln(pretreatment level assay cutoff).
e Used as an indicator of treatment efficacy.
TABLE 3 Associationsa between percent change in isotype responses to SWA, SmTAL1, SEA, SmTAL2, AHW, and ASP2 and pretreatment S.
mansoni or hookworm infection intensity
Antigen and antibody
S. mansoni Hookworm
Adjusted % boost (95% CI) P valueb Adjusted % boost (95% CI) P value
SWA
IgE 0.1 (2.8, 2.7) 0.95 1.8 (0.5, 4.1) 0.13
IgG1 4.3 (1.2, 7.5) 0.01 1.8 (0.7, 4.4) 0.16
IgG4 1.0 (8.9, 7.6) 0.81 3.7 (3.2, 11.1) 0.30
TAL1
IgE 3.8 (3.26, 11.43) 0.29c 0.3 (5.4, 6.4) 0.91
IgG1 11.2 (5.8, 16.8) 0.001 1.1 (5.2, 3.1) 0.59
IgG4 14.7 (7.8, 21.9) 0.001 0.3 (4.8, 5.8) 0.90
SEA
IgE 2.1 (1.2, 5.5) 0.21 1.9 (0.9, 4.7) 0.18
IgG1 1.2 (1.2, 3.6) 0.34 1.6 (0.4, 3.6) 0.11
IgG4 0.6 (6.0, 5.2) 0.84d 0.9 (5.4, 3.8) 0.70
TAL2
IgE 4.6 (3.4, 13.3) 0.26 1.9 (4.6, 8.9) 0.57
IgG1 2.7 (0.5, 6.0) 0.10 1.0 (1.7, 3.7) 0.47
IgG4 5.6 (1.1, 10.3) 0.01 0.7 (4.3, 3.0) 0.71
HW
IgE 11.1 (6.3, 31.8) 0.22 3.5 (16.2, 11.3) 0.62
IgG1 1.3 (17.6, 24.6) 0.90e 21.2 (33.5,6.7) 0.01f
IgG4 2.9 (0.0, 6.0) 0.13 4.5 (6.8,2.2) 0.0001
ASP2
IgE
IgG1 2.3 (2.4, 7.2) 0.33 0.6 (4.4, 3.3) 0.75
IgG4 2.0 (10.8, 7.5) 0.66g 1.5 (8.9, 6.4) 0.69
a Percent change in isotype responses with each unit increase in ln(epg), or equivalently, an increase in epg by a multiple of e (roughly 2.71828), adjusting for age and sex using
multiple regression analysis.
b Likelihood ratio (LR) test.
c Significant age-pretreatment infection intensity interaction (2 [df 1] by LR test 5.08, P 0.02): adjusted percent boost for the group aged10 years5.6 (95% CI,
15.3, 5.3); adjusted percent boost for the group aged10 yrs 11.1 (95% CI, 1.4, 21.9) .
d Significant age-pretreatment infection intensity interaction (2 [df 1] by LR test 4.02, P 0.04): adjusted percent boost for the group aged10 years7.0 (95% CI,
14.7, 1.4); adjusted percent boost for the group aged10 years 4.3 (95% CI,3.0, 12.3).
e Significant age-pretreatment infection intensity interaction (2 [df 1] by LR test 4.17, P 0.04): adjusted percent boost for the group aged10 years21.3 (95% CI,
42.8, 8.3); adjusted percent boost for the group aged10 years 21.4 (95% CI,7.3, 59.1).
f Significant age-pretreatment infection intensity interaction (2 [df 1] by LR test 4.55, P 0.03): adjusted percent boost for the group aged10 years36.1 (95% CI,
50.6,17.5); adjusted percent boost for the group aged10 years8.2 (95% CI,26.3, 14.4).
g Significant age-pretreatment infection intensity interaction (2 [df 1] by LR test 8.42, P 0.004): adjusted percent boost for the group aged10 years16.6 (95% CI,
27.6,3.8); adjusted percent boost for the group aged10 years 9.9 (95% CI,2.5, 24.0).
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administration of praziquantel and albendazole is increasingly
called for.
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